<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290195</url>
  </required_header>
  <id_info>
    <org_study_id>2AA</org_study_id>
    <nct_id>NCT04290195</nct_id>
  </id_info>
  <brief_title>Use of Ziv Aflibercept in Different Retinal Diseases</brief_title>
  <official_title>Safety and Efficacy of Ziv Aflibercept in Myopic Choroidal Neovascularisation ,Central Retinal Vein Occlusion and Resistant Diabetic Macular Edema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amin El Sayed Nawar</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tanta University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Tanta University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A prospective interventional case series study was conducted on 20 eyes of 20 patients with
      active myopic choroidal neovascularisation (CNV) ,20 eyes with resistant diabetic macular
      edema and 15 eyes with non ischaemic central retinal vein occlusion(CRVO) after approval of
      the Ethical Committee of the Faculty of Medicine, Tanta University . All procedures were
      carried out under the tenets of the Helsinki Declaration. Written consent was provided by all
      participants after discussing the procedure, alternative treatment plans, follow-up
      schedules, and possible benefits and risks.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Intravitreal injection of 1.25 mg of ziv aflibercept was done in different retinal diseases
      including myopic CVN,resistant diabetic macular edema to previous ranibizumab injection and
      non ischaemic CRVO .Thorough ophthalmic evaluation was done including BCVA(best corrected
      visual acuity) ,anterior and posterior segment examination ,fundus fluorescein angiography
      and OCT(optical coherence tomography) were performed for all patients .Injection was repeated
      as PRN(pro re nata) method after one month if persistent intraretinal or subretinal fluid was
      found.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 1, 2019</start_date>
  <completion_date type="Actual">January 1, 2020</completion_date>
  <primary_completion_date type="Actual">December 1, 2019</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Resistant diabetic macular edema,non ischaemic central retinal vein occlusion and myopic choroidal neovascularisation</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Improvement of BCVA by log MAR(minimum angle of resolution) and reduction of CMT after intravitreal injection</measure>
    <time_frame>6 months</time_frame>
    <description>To assess if there is improvement of BCVA(Best corrected visual acuity) and reduction of the CMT (central macular thickness) after intravitreal injection of zivaflibercept</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">55</enrollment>
  <condition>Central Retinal Vein Occlusion With Macular Edema</condition>
  <arm_group>
    <arm_group_label>ziv aflibercept patients</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 eyes of myopic CNV,20 eyes with resistant diabetic macular edema and 15 eyes with non ischaemic CRVO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziv-Aflibercept 25 MG/ML [Zaltrap]</intervention_name>
    <description>Intravitreal injection of 1.25 mg of ziv aflibercept in patients</description>
    <arm_group_label>ziv aflibercept patients</arm_group_label>
    <other_name>zaltrap</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The study included treatment naive patients suffering from recently diagnosed active
             myopic subfoveal or juxtafoveal CNV less than 2 months documented by fundus
             fluorescein angiography (FFA)and optical coherence tomography (OCT ) , pathological
             myopia more than 6 D was included .

        Exclusion Criteria:

          -  Previous intraocular surgery .

          -  Coincident retinal pathology as diabetic retinopathy, retinal vein occlusion .

          -  CNV due to other causes like age related macular degeneration ,angioid streaks,trauma
             and choroiditis.

          -  Extrafoveal myopic CNV .

          -  Patients received other lines of treatment for CNV like photodynamic therapy ,laser
             photocoagulation or intravitreal injection of triamcinolone or other anti
             VEGF(vascular endothelial growth factor) agents.

          -  Known glaucoma , clinical suspicion of glaucoma or IOP(intraocular pressure) more than
             20 mmHg.

          -  Prior ocular inflammation.

          -  The presence of retinal degeneration.

          -  Patients who didnot complete 6 months of follow up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>31 Years</minimum_age>
    <maximum_age>63 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Tanta University</name>
      <address>
        <city>Tanta</city>
        <state>El Gharbia</state>
        <zip>31111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <link>
    <url>http://www.ncbi.nlm.nih.gov</url>
    <description>medical journal that contains multiple papers</description>
  </link>
  <results_reference>
    <citation>Chan WM, Ohji M, Lai TY, Liu DT, Tano Y, Lam DS. Choroidal neovascularisation in pathological myopia: an update in management. Br J Ophthalmol. 2005 Nov;89(11):1522-8. Review.</citation>
    <PMID>16234465</PMID>
  </results_reference>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 23, 2020</study_first_submitted>
  <study_first_submitted_qc>February 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2020</study_first_posted>
  <last_update_submitted>February 26, 2020</last_update_submitted>
  <last_update_submitted_qc>February 26, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Tanta University</investigator_affiliation>
    <investigator_full_name>Amin El Sayed Nawar</investigator_full_name>
    <investigator_title>Amin Nawar MD.Lecturer of Ophthalmology</investigator_title>
  </responsible_party>
  <keyword>myopic choroidal neovascularisation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Macular Edema</mesh_term>
    <mesh_term>Retinal Vein Occlusion</mesh_term>
    <mesh_term>Choroidal Neovascularization</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

